Glovista Investments LLC held its stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,899 shares of the company’s stock at the end of the fourth quarter. Glovista Investments LLC’s holdings in Merck & Co. were worth $406,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in MRK. Blume Capital Management Inc. increased its stake in Merck & Co. by 14.0% in the third quarter. Blume Capital Management Inc. now owns 1,710 shares of the company’s stock worth $107,000 after buying an additional 210 shares during the period. Roble Belko & Company Inc increased its stake in Merck & Co. by 16.6% in the third quarter. Roble Belko & Company Inc now owns 2,102 shares of the company’s stock worth $131,000 after buying an additional 300 shares during the period. NewSquare Capital LLC increased its stake in Merck & Co. by 3.9% in the third quarter. NewSquare Capital LLC now owns 2,187 shares of the company’s stock worth $137,000 after buying an additional 83 shares during the period. Mascoma Wealth Management LLC purchased a new stake in Merck & Co. during the fourth quarter worth $135,000. Finally, Cascade Investment Advisors Inc. purchased a new stake in Merck & Co. during the fourth quarter worth $135,000. Hedge funds and other institutional investors own 74.10% of the company’s stock.
Merck & Co., Inc. (NYSE:MRK) traded down 1.06% during midday trading on Friday, reaching $61.89. 11,164,982 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $63.91 and a 200 day moving average price of $62.49. Merck & Co., Inc. has a 52 week low of $53.06 and a 52 week high of $66.80. The company has a market cap of $169.92 billion, a price-to-earnings ratio of 43.89 and a beta of 0.79.
Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Thursday, February 2nd. The company reported $0.89 EPS for the quarter, meeting analysts’ consensus estimates of $0.89. Merck & Co. had a net margin of 14.30% and a return on equity of 24.08%. The company earned $10.10 billion during the quarter, compared to analyst estimates of $10.22 billion. During the same period last year, the business earned $0.93 earnings per share. Merck & Co.’s revenue was down 1.0% compared to the same quarter last year. Analysts anticipate that Merck & Co., Inc. will post $3.81 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, April 7th. Shareholders of record on Wednesday, March 15th were given a dividend of $0.47 per share. The ex-dividend date was Monday, March 13th. This represents a $1.88 annualized dividend and a yield of 3.04%. Merck & Co.’s payout ratio is presently 92.61%.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/04/21/merck-co-inc-mrk-stake-held-by-glovista-investments-llc-updated-updated.html.
MRK has been the subject of a number of recent research reports. Cowen and Company reiterated a “market perform” rating and set a $68.00 price objective on shares of Merck & Co. in a research report on Tuesday, April 11th. HSBC Holdings plc downgraded Merck & Co. from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. Vetr upgraded Merck & Co. from a “strong sell” rating to a “sell” rating and set a $58.15 price objective for the company in a research report on Thursday, January 12th. Jefferies Group LLC reiterated an “underperform” rating and set a $48.00 price objective on shares of Merck & Co. in a research report on Thursday, January 12th. Finally, Piper Jaffray Companies upgraded Merck & Co. from a “neutral” rating to an “overweight” rating and set a $72.00 price objective for the company in a research report on Thursday, January 12th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $67.74.
In other Merck & Co. news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co. stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $64.51, for a total transaction of $322,550.00. Following the completion of the sale, the director now directly owns 5,100 shares in the company, valued at $329,001. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael J. Holston sold 91,959 shares of Merck & Co. stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $63.96, for a total transaction of $5,881,697.64. Following the sale, the executive vice president now owns 105,559 shares of the company’s stock, valued at $6,751,553.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,809 shares of company stock valued at $10,261,846. 0.05% of the stock is currently owned by company insiders.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Co. Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Co. Inc. and related companies.